Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial

Kiemeneij, Ferdinand; Serruys, Patrick W.; Macaya, T. Carlos; Rutsch, Wolfgang; Heyndrickx, Guy R.; Albertsson, Per; Fajadet, Jean; Legrand, Victor; Materne, P.; Belardi, Jorge; Sigwart, Ulrich; Colombo, Antonio; Goy, Jean‐Jácques; Disco, Clemens; Morel, Marie-Angèle

doi:10.1016/s0735-1097(01)01207-4

Cited by 165 publications

(75 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although longer-term follow-up would have been enlightening, it seems unlikely that the cost-effectiveness of sirolimus-eluting stents would be less favorable with longer follow-up. Previous studies suggest that the restenosis process is largely complete after 12 months, 18 so later events are related predominantly to atherosclerosis progression, which would be unlikely to be altered by a drug-eluting stent. Moreover, exclusion of outpatient medication costs (except for clopidogrel) from our analysis may also have biased our analysis slightly against sirolimus-eluting stents.…”

Section: Study Limitationsmentioning

confidence: 98%

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses

Cohen

Bakhai²,

Shi³

et al. 2004

Circulation

201

View full text Add to dashboard Cite

Section: Study Limitationsmentioning

confidence: 98%

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses

Cohen

Bakhai²,

Shi³

et al. 2004

Circulation

201

View full text Add to dashboard Cite

“…This may represent no more than the play of chance, as the authors suggest. Only one other study (BENESTENT,114 ) comparing conventional balloon angioplasty and stents) reported details of deaths from cancer separately. Combining figures from these two RCTs confirms that the SOS result appears to be sustained (p = 0.002 on Fisher's exact test).…”

Section: Mortalitymentioning

confidence: 99%

Coronary artery stents: a rapid systematic review and economic evaluation

Hill¹,

Bagust²,

Bakhai³

et al. 2004

Health Technol Assess

143

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

“…The few studies including longer-term follow-up of the firstgeneration Palmaz-Schatz stent also have focused on late stability of the target lesion. [1][2][3] Repeat revascularization of the target lesion resulting from restenosis is the most common event during this interval. The interest in restenosis events recently reached a crossroads with the advent of drug-eluting stents that have demonstrated their ability to reduce restenosis rates by roughly 70% compared with bare metal stents.…”

mentioning

confidence: 99%

Beyond Restenosis

Cutlip

Chhabra²,

Baim³

et al. 2004

Circulation

275

View full text Add to dashboard Cite

Background-In the first year after coronary stent implantation, clinical failures are driven mainly by procedural complications and restenosis, but the subsequent relative contributions of restenosis and disease progression to late failures are less clear. Methods and Results-We observed 1228 patients for 5 years after the implantation of stents as part of pivotal second-generation coronary stent trials. Clinical events of death, myocardial infarction, repeat revascularization, and repeat hospitalization for acute coronary syndrome or congestive heart failure were attributed to the index stented (target) lesion or other distinct sites (either in the target or other coronary vessels) and further classified as procedural, restenosis, or nonrestenosis. During the first year the hazard rate was 18.3% for target-lesion events and 12.4% for events unrelated to the target lesion. After the first year the average annual hazard rate was 1.7% for target-lesion events and 6.3% for nontarget-lesion events. By the fifth year, restenosis events occurred in 20.3% of patients, whereas 30-day procedural complications or later nonrestenosis events occurred in 37.9%, including 11.4% who also experienced a restenosis event, for a combined cumulative event rate of 46.4%. Diabetes mellitus and multivessel disease were independently associated with increased risk for both restenosis and nonrestenosis events. Conclusion-In a low-risk clinical trial population, the clinical outcome beyond 1 year after stenting is determined by a high rate of events related to disease progression in segments other than the stented lesion, which itself remains relatively stable.

show abstract

Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial

Abstract: The original 10% absolute difference in TLR in favor of the stent group has remained unchanged at five years, emphasizing the long-term stability of the stented target site.

Cited by 165 publications

References 9 publications

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses

Coronary artery stents: a rapid systematic review and economic evaluation

Beyond Restenosis

Contact Info

Product

Resources

About